John Libbey Eurotext

Gériatrie et Psychologie Neuropsychiatrie du Vieillissement

MENU

Symptomatic treatments in Alzheimer's disease in 2016: a study from Memory centers in France Volume 14, issue 3, Septembre 2016

Figures

  • Figure 1

Tables

Authors
1 CMRR Centre, CHRU Tours et université François Rabelais, Tours, France
2 CMRR Champagne Ardenne, CHU Reims, France
3 CMRR Aquitaine, CHU Bordeaux, France
4 CMRR Pays Loire, CHU Nantes, France
5 CMRR Bretagne, CHU Rennes, France
6 Service de gérontopsychiatrie, CHRU Tours, France
7 CMRR PACA, CHU Marseille, France
* Tirés à part

Cholinesterase inhibitors and memantine are used from 15 years, in Alzheimer's disease. Benefits have been demonstrated according to cognition, activities of daily living, affective symptoms and behavior, and global impression of change. The aims of this paper are: 1) to describe how these treatments are used in France with a sample survey managed by the national federation of the french CMRR; 2) to study data about efficacy, safety, medicoeconomic impacts and how they are used in Europe.